Compare iShares MSCI ACWI ETF (ACWI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI ACWI ETF trades at $155.58, while Novo Nordisk A/S trades at $49.26 (market cap $220.20B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| ACWI | NVO | |
|---|---|---|
52-Week High | $159.97 | $71.70 |
52-Week Low | $128.32 | $35.29 |
Market Cap | — | $220.20B |
Sector | — | Health |
Enterprise Value | — | $239.16B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Novo Nordisk (NVO) trades at $49.64, down 1.57% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with $309.1B revenue in 2025 and impressive profitability metrics including 37.2% net income margin and 71.4% ROE. Recent earnings beats and Medicare's GLP-1 coverage expansion for weight-loss drugs provide positive catalysts. Analyst consensus remains strongly bullish with 22 buy ratings versus only 3 sell recommendations.
NVO presents a compelling investment case with strong earnings growth, market leadership in GLP-1 therapies, and favorable valuation at 11.82 P/E. Key risks include intensifying competition in obesity drugs and potential pricing pressures. The stock's current technical setup near support at $49 suggests potential for rebound, supported by institutional confidence and positive business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
